Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial; [کارآزمایی بالینی تصادفی Persianpolypill شدهی مروری بر درمان ترکیبی با دوز ثابت برای پیشگیری ثانویه از حوادث نامطلوب قلبی- عروقی و نتایج اولیهی] Publisher



Sadeghi M1 ; Roohafza H1 ; Nateghi A2 ; Sarrafzadegan N3 ; Mansourian M4 ; Najafian J5 ; Bostan F1 ; Hoseini SG6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2024


Abstract

Background: This article is an update on our previous review of clinical studies on the role of polypills in the secondary prevention of cardiovascular diseases (CVD). We also present the preliminary results of the Persian Polypill study. Methods: Persian Polypill is a randomized clinical trial with two parallel arms on hospitalized patients due to acute myocardial infarction (AMI). It is planned that 1100 patients will be randomly assigned to one of the two arms of Polypill or usual care and will be followed up for 34 months. The primary outcome will be a composite clinical outcome of major adverse cardiovascular events (MACE), and the secondary outcome will be the cost-effectiveness of polypill treatment. Findings: We identified ten completed studies and two ongoing trials in which at least 10% of participants had CVD. The evaluation of these studies showed the lack of research in low- and middle-income countries about the role of polypill in secondary prevention of CVD and limited information about cost-effectiveness resulting from clinical trials. In Persian Polypill, so far, 624 patients admitted to three hospitals due to AMI have been included in the study. The average age of patients is 60.9 ± 8.7 and 506 are male (81.1%). Overall, 94.4% of the patients underwent percutaneous coronary intervention in the hospital, and 26.3% had hospital complications. Conclusion: The final results of this study can compensate for the gap in the past studies. They may confirm the role of polypill in the initial management of AMI and long-term secondary prevention in these patients. © 2024 Isfahan University of Medical Sciences(IUMS). All rights reserved.
Related Docs
View other Related Docs
1. Fixed Dose Combination Therapy for Secondary Prevention of Major Cardiovascular Events: Review of Literature and Design for Persian Polypill, a Randomized Clinical Trial, Current Problems in Cardiology (2022)
2. Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases (Polyiran): A Pragmatic, Cluster-Randomised Trial, The Lancet (2019)
3. Polypill for the Prevention of Cardiovascular Disease (Polyiran): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial, European Journal of Preventive Cardiology (2015)
4. Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting, Global Heart (2024)
5. Medication Adherence With Polypill in Cardiovascular Disease and High-Risk Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Involving 7364 Participants, Current Problems in Cardiology (2024)
6. Background and Design of a 5-Year St Elevation Myocardial Infarction Cohort in Isfahan, Iran: Semi-Ci Study, ARYA Atherosclerosis (2022)
7. Total Cardiovascular Risk Approach to Improve Efficiency of Cardiovascular Prevention in Resource Constrain Settings, Journal of Clinical Epidemiology (2011)
8. Effectiveness of Tenecteplase Versus Streptokinase in Treatment of Acute Myocardial Infarction: A Meta-Analysis, Tehran University Medical Journal (2018)
Experts (# of related papers)
View all Related Experts
Nizal Sarrafzadegan (27)
Masoumeh Sadeghi (27)
Other Related Docs
9. A Cardiovascular Risk Assessment Model According to Behavioral, Psychosocial and Traditional Factors in Patients With St-Segment Elevation Myocardial Infarction (Cras-Mi): Review of Literature and Methodology of a Multi-Center Cohort Study, Current Problems in Cardiology (2023)
10. Persian Registry of Cardiovascular Disease (Prove): Design and Methodology, ARYA Atherosclerosis (2017)
11. Isfahan Healthy Heart Program, Sample Size and Sampling Structure: A Comprehensive Report, Journal of Isfahan Medical School (2016)
12. Prevalence of Total Cholesterol in Iran: Systematic Review and Meta-Analysis, Journal of Mazandaran University of Medical Sciences (2015)
13. The Pattern of In-Hospital Mortality of Myocardial Infarction and Associated Factors in Iran: A National Study, Journal of Isfahan Medical School (2015)
14. Cardiovascular Disease in the Eastern Mediterranean Region: Epidemiology and Risk Factor Burden, Nature Reviews Cardiology (2018)
15. The Relationship Between Nut Consumption and Premature Coronary Artery Disease in a Representative Sample of Iranians: Iran-Premature Coronary Artery Disease (Ipad) Study, Public Health Nutrition (2023)
16. Aspirin Resistance Status As Determined by Urinary Thromboxane B 2 (Txb2) Level in Patients With Ischemic Heart Disease and Its Relationship With Severity of Coronary Artery Disease, Journal of Isfahan Medical School (2011)
17. Comparison of Survival Rate and Complications of Percutaneous Coronary Intervention, Coronary Artery Bypass Graft, and Medical Treatment in Patients With Left Main And/Or Three Vessel Diseases, ARYA Atherosclerosis (2020)
18. Reperfusion Therapies and In-Hospital Outcomes for St-Elevation Myocardial Infarction in Europe: The Acvc-Eapci Eorp Stemi Registry of the European Society of Cardiology, European Heart Journal (2021)
19. Secular Trends in Cardiovascular Mortality in Iran, With Special Reference to Isfahan, Acta Cardiologica (1999)
20. Factors Affecting Outcome of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction, ARYA Atherosclerosis (2013)
21. Differences Between the Characteristics of Ihd Patients Undergoing Different Treatment Modalities Who Adhere to Cardiac Rehabilitation Programs, Iranian Heart Journal (2014)
22. Current Status of the Clinical Epidemiology of Myocardial Infarction in Men and Women: A National Cross-Sectional Study in Iran, International Journal of Preventive Medicine (2015)
23. Availability and Affordability of Medicines and Cardiovascular Outcomes in 21 High-Income, Middle-Income and Low-Income Countries, BMJ Global Health (2020)
24. Cost-Effectiveness Evaluation of Aspirin in Primary Prevention of Myocardial Infarction Amongst Males With Average Cardiovascular Risk in Iran, Research in Pharmaceutical Sciences (2017)
25. The Comparison of Procedural and Clinical Outcomes of Thrombolytic-Facilitated and Primary Percutaneous Coronary Intervention in Patients With Acute St-Elevation Myocardial Infarction (Stemi): Findings From Prove/Acs Study, ARYA Atherosclerosis (2020)
26. Heart Rate and Cardiovascular Events: A Nested Case-Control in Isfahan Cohort Study, Archives of Iranian Medicine (2014)
27. Analysis of Traditional Risk Factors on St-Segment Elevation Myocardial Infarction Characteristics; [بررسی عوامل خطر سنتی مرتبط با ویژگیهای بالینی بیماران انفارکتوس میوکارد با بالارونده قطعه St], Journal of Isfahan Medical School (2024)
28. Development of the First Iranian Clinical Practice Guidelines for the Diagnosis, Treatment, and Secondary Prevention of Acute Coronary Syndrome, Journal of Research in Medical Sciences (2024)
29. Secondary Prevention Medications in 17 Countries Grouped by Income Level (Pure): A Prospective Cohort Study, Journal of the American College of Cardiology (2025)
30. Predictive Factors of Short-Term Survival From Acute Myocardial Infarction in Early and Late Patients in Isfahan and Najafabad, Iran, ARYA Atherosclerosis (2016)
31. Incidence of Cardiovascular Diseases in an Iranian Population: The Isfahan Cohort Study, Archives of Iranian Medicine (2013)
32. Design and Methodology of Heart Failure Registry: Results of the Persian Registry of Cardiovascular Disease, ARYA Atherosclerosis (2019)
33. Risk of Fatal and Nonfatal Coronary Heart Disease and Stroke Events Among Adult Patients With Hypertension: Basic Markov Model Inputs for Evaluating Cost-Effectiveness of Hypertension Treatment: Systematic Review of Cohort Studies, Journal of Pharmaceutical Health Services Research (2021)
34. Methods of Sampling and Sample Size Determination of a Comprehensive Integrated Community-Based Interventional Trial: Isfahan Healthy Heart Program, ARYA Atherosclerosis (2018)
35. Can Doubling the Maintenance Dose of Clopidogrel Prevent From Early Stent Thrombosis After the Primary Percutaneous Coronary Intervention?, ARYA Atherosclerosis (2011)
36. Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries, New England Journal of Medicine (2014)
37. Audit and Quality Assessment of National Persian Registry of Cardiovascular Disease(N-Prove) in Terms of Comorbidities, Angiography, and Angioplasty Characteristics in Iran, ARYA Atherosclerosis (2024)
38. Medical Therapy Versus Percutaneous Coronary Intervention or Coronary Artery Bypass Graft in Stable Coronary Artery Disease; a Systematic Review and Meta-Analysis of Randomized Clinical Trials, ARYA Atherosclerosis (2022)
39. Survey of Coronary Catheterization Laboratory Activity in Iran During the Coronavirus Disease-2019 Pandemic, ARYA Atherosclerosis (2021)
40. Effects of Enhanced External Counterpulsation on Anginal Symptoms and Improvements in Objective Measures of Myocardial Ischaemia, Cardiovascular Journal of South Africa (2007)
41. Blood Group Types and Clinical, Procedural, and Adverse Outcomes in St-Elevated Myocardial Infarction Patients: A 3-Year Cohort in Iran, Journal of Research in Medical Sciences (2023)
42. Care of Patients With St-Elevation Myocardial Infarction: An International Analysis of Quality Indicators in the Acute Coronary Syndrome Stemi Registry of the Eurobservational Research Programme and Acvc and Eapci Associations of the European Society of Cardiology in 11 462 Patients, European Heart Journal: Acute Cardiovascular Care (2023)
43. Clinical Characteristics, Management and 1-Year Outcomes of Patients With Acute Coronary Syndrome in Iran: The Iranian Project for Assessment of Coronary Events 2 (Ipace2), BMJ Open (2015)
44. Immediate Results and Six-Month Outcomes After Percutaneous Coronary Intervention in a Referral Heart Center in Isfahan, Iran, ARYA Atherosclerosis (2011)
45. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the Gbd 2019 Study, Journal of the American College of Cardiology (2020)
46. Explaining the Decline in Coronary Heart Disease Mortality Rate Using Impact Model: Estimation of the Changes in Risk Factors and Treatment Uptake in Iran Between 2007 and 2016, ARYA Atherosclerosis (2023)
47. Coronary Bypass Surgery Versus Percutaneous Coronary Intervention: Cost-Effectiveness in Iran: A Study in Patients With Multivessel Coronary Artery Disease, International Journal of Technology Assessment in Health Care (2014)
48. Prognostic Validation of a Non-Laboratory and a Laboratory Based Cardiovascular Disease Risk Score in Multiple Regions of the World, Heart (2018)
49. Trends of 28 Days Case Fatality Rate After First Acute Myocardial Infarction in Isfahan, Iran, From 2000 to 2009, ARYA Atherosclerosis (2015)
50. Availability and Nature of Cardiac Rehabilitation by Province in Iran: A 2018 Update of Iccpr's Global Audit, Journal of Research in Medical Sciences (2023)